Patents Assigned to Amgen
  • Beta Secretase Genes
    Publication number: 20070191298
    Abstract: Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides.
    Type: Application
    Filed: February 28, 2007
    Publication date: August 16, 2007
    Applicant: AMGEN INC.
    Inventors: Martin Citron, Robert Vassar, Brian Bennett
  • TALL-1 receptor molecules and uses thereof
    Patent number: 7256015
    Abstract: The present invention provides tumor necrosis factor and apoptosis ligand-related leukocyte-expressed ligand 1 receptor (TALL-1R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TALL-1R polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TALL-1R polypeptides.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: August 14, 2007
    Assignee: Amgen Inc.
    Inventor: Hailing Hsu
  • Beta-secretase modulators and methods of use
    Publication number: 20070185144
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: November 10, 2006
    Publication date: August 9, 2007
    Applicant: Amgen Inc.
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian Albrecht, Michael Bartberger, James Brown, Ryan Brown, Stuart Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang
  • Aminopyrimidine compounds and methods of use
    Publication number: 20070185133
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Application
    Filed: December 16, 2005
    Publication date: August 9, 2007
    Applicant: Amgen, Inc.
    Inventors: Adrian Smith, Paul Brennan, Frenel DeMorin, Gang Liu, Nick Paras, Daniel Retz, Elizabeth Rainbeau
  • Fused heterocyclic compounds
    Patent number: 7253179
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: August 7, 2007
    Assignee: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Jeffrey Thomas Mihalic
  • Inhibitors of 11-?-hydroxy steroid dehydrogenase type 1
    Patent number: 7253196
    Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: August 7, 2007
    Assignees: Amgen, Inc., Biovitrum AB
    Inventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
  • Beta Secretase Polypeptides
    Publication number: 20070173477
    Abstract: Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides.
    Type: Application
    Filed: February 28, 2007
    Publication date: July 26, 2007
    Applicant: AMGEN INC.
    Inventors: Martin Citron, Robert Vassar, Brian Bennett
  • Thiazole compounds and methods of use
    Publication number: 20070173506
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: January 11, 2007
    Publication date: July 26, 2007
    Applicant: AMGEN INC.
    Inventors: Qingping Zeng, John Allen, Matthew Bourbeau, Celia Dominguez, Christopher Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew Lee, Aiwen Li, Qingyian Liu, James Rider, Seifu Tadesse, Andrew Tasker, Vellarkad Viswanadhan, Xianghong Wang, Kurt Weiler, George Wohlhieter, Guomin Yao, Chester Yuan
  • Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
    Patent number: 7247741
    Abstract: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: July 24, 2007
    Assignees: PTC Therapeutics, Inc., Amgen Inc.
    Inventors: Richard G. Wilde, Ellen M. Welch, James Jan Takasugi, Neil G. Almstead, Steven Marc Rubenstein, Holger Beckmann
  • Pharmaceutical compositions of fibrinolytic agent
    Patent number: 7244426
    Abstract: Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: July 17, 2007
    Assignee: Amgen, Inc.
    Inventors: Brent S. Kendrick, Brian A. Peterson
  • Production of glycoproteins using manganese
    Publication number: 20070161084
    Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.
    Type: Application
    Filed: December 6, 2006
    Publication date: July 12, 2007
    Applicant: AMGEN INC.
    Inventors: Christopher Crowell, Gustavo Grampp
  • Method for generating F(ab')2 antibody fragments
    Publication number: 20070154471
    Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.
    Type: Application
    Filed: September 18, 2006
    Publication date: July 5, 2007
    Applicant: Amgen Inc.
    Inventors: John Hui, Mitsuru Haniu, Hsieng Lu
  • TNF binding proteins
    Patent number: 7238776
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: July 3, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • CXCR3 antagonists
    Publication number: 20070149557
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment of conditions and diseases mediated by a chemokine receptor. In particular, the compounds of the invention modulate the CXCR3 chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
    Type: Application
    Filed: November 21, 2006
    Publication date: June 28, 2007
    Applicant: Amgen Inc.
    Inventors: Tassie Collins, Julio Medina, Feng Xu, Liusheng Zhu
  • Uses of myostatin antagonists
    Publication number: 20070149458
    Abstract: The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-?, and other muscle-related, metabolic and inflammatory disorders by administering myostatin antagonists to subjects suffering from such disorders.
    Type: Application
    Filed: December 6, 2006
    Publication date: June 28, 2007
    Applicant: Amgen Inc.
    Inventors: Hq Han, Alexander DePaoli, John Lu, Jin Wang
  • Antibodies that bind receptor protein designated 2F1
    Patent number: 7235238
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 26, 2007
    Assignee: Amgen Inc.
    Inventors: Patricia Parnet, John E. Sims
  • Antagonists of interleukin-15
    Patent number: 7235240
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: June 26, 2007
    Assignee: Amgen Inc.
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • IRAK-4: compositions and methods of use
    Patent number: 7235635
    Abstract: The present invention provides nucleic acids and polypeptides for IRAK-4, a novel member of the IRAK family of protein kinases. Members of the IRAK family are indispensable signal transducer for members of the IL-1R/Toll family of transmembrane receptors, including IL-1 receptors, IL-18 receptors and LPS receptors. IRAK-4 sequences from human and mouse are provided, as are methods for identifying compounds useful in the treatment or prevention of inflammatory diseases.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: June 26, 2007
    Assignee: Amgen Inc.
    Inventors: Holger Wesche, Shyun Li
  • Thrombopoietic compounds
    Publication number: 20070142295
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Application
    Filed: December 22, 2006
    Publication date: June 21, 2007
    Applicant: AMGEN INC.
    Inventors: Chuan-Fa Liu, Ulrich Feige, Janet Cheetham
  • Host cells and culture methods
    Publication number: 20070141674
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Application
    Filed: December 6, 2006
    Publication date: June 21, 2007
    Applicant: AMGEN INC.
    Inventor: Christopher Crowell